Physician profile
Jason E Schend
NPI 1861833774
$12,537.39
in general payments reported to CMS, 2019-2025
27 companies · $656 in 2025
The $656 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $570 · 2020: $575 · 2021: $805 · 2022: $7,284 · 2023: $2,448 · 2024: $200 · 2025: $656.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,850 · Food and Beverage: $1,428 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,850.00 |
| Food and Beverage | $1,428.28 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $8,929.43 | 2019-2025 | Tezspire, Fasenra |
| Glaxosmithkline, LLC. | $751.56 | 2019-2025 | Nucala, Trelegy Ellipta |
| Genentech USA, INC. | $382.24 | 2020-2025 | Xolair |
| Regeneron Healthcare Solutions, INC. | $316.61 | 2019-2025 | Dupixent |
| Pharming Healthcare, INC. | $237.77 | 2019-2023 | Ruconest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $220.55 | 2020-2022 | |
| Grifols USA, LLC | $203.64 | 2020-2022 | |
| Ars Pharmaceuticals Operations, INC. | $166.32 | 2025 | Neffy |
| Genzyme Corporation | $146.62 | 2020-2025 | |
| Abbvie INC. | $127.28 | 2021-2023 | Rinvoq |
| Novartis Pharmaceuticals Corporation | $116.73 | 2023-2024 | |
| Blueprint Medicines Corporation | $112.40 | 2023 | Ayvakit |
| Philips North America LLC | $105.24 | 2021-2022 | |
| Pfizer INC. | $104.16 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $95.29 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $92.48 | 2019-2023 | Auvi-Q |
| Amgen INC. | $86.72 | 2019-2022 | |
| Csl Behring | $83.61 | 2021-2022 | |
| Horizon Therapeutics Plc | $48.10 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $40.30 | 2020 | |
| Ionis Pharmaceuticals, INC. | $40.00 | 2025 | Dawnzera |
| Shire North American Group INC | $39.81 | 2019 | |
| Cycle Pharmaceuticals INC | $34.57 | 2025 | Sajazir |
| Biocryst Pharmaceuticals, INC. | $16.06 | 2020 | |
| Biocryst US Sales Co., LLC | $15.52 | 2021 | |
| Optinose US, INC. | $13.45 | 2022 | |
| Mayne Pharma Commercial LLC | $10.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Schend listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.